BLFS Form 144: Insider Sells 500 Shares

BioLife Solutions, Inc. (BLFS) filed a Form 144 reporting a transaction involving 500 common shares on 03/09/2026 tied to the exercise of stock options and settled for cash.

Rhea-AI Filing Summary

BioLife Solutions, Inc. (BLFS) filed a Form 144 reporting a transaction involving 500 common shares on 03/09/2026 tied to the exercise of stock options and settled for cash. The filing also lists recent 10b5-1 sales: 96,923 shares on 03/05/2026 for $1,953,163.22, 418 shares on 03/03/2026 for $8,669.32, and 335 shares on 01/06/2026 for $8,572.65.

Insights

Insider Transactions Analyst

Routine insider disposition activity via option exercise and 10b5-1 plan; no company proceeds reported beyond cash settlement.

The filing records a 500-share transaction on 03/09/2026 described as an exercise of stock options that settled for cash. It separately itemizes multiple prior 10b5-1 sales with explicit share counts and gross proceeds.

These entries are administrative disclosures of insider trading activity; timing and cash-flow counterparty details beyond the settlement method are not provided in the excerpt. Subsequent filings may show additional transactions or updated holdings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does BLFS Form 144 report?

It reports an insider transaction of 500 common shares on 03/09/2026 tied to option exercise. The filing also lists prior 10b5-1 sales with share counts and gross proceeds for each trade.

Who executed the transactions reported in BLFS Form 144?

The excerpt lists trades affiliated with an issuer action and prior 10b5-1 sales by a named plan participant. Specific individual names appear in the prior-sales lines but the excerpt ties the 500-share action to an issuer option exercise.

How much cash was reported from recent 10b5-1 sales in the filing?

The filing shows gross proceeds of $1,953,163.22 for 96,923 shares on 03/05/2026, and smaller proceeds of $8,669.32 and $8,572.65 for the other listed trades.

Does the Form 144 disclose shares outstanding or dilution impact for BLFS?

No. The excerpt does not state total shares outstanding or quantify dilution. It lists specific insider sales and option exercise details but does not provide company-wide outstanding share counts.

Were the recent trades part of a 10b5-1 plan?

Yes. The filing explicitly identifies multiple prior transactions as 10b5-1 sales, including the 96,923-share sale on 03/05/2026, indicating planned selling arrangements for those trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:38 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001683151
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BioLife Solutions, Inc.
SEC File Number	001-36362
Address of Issuer	3303 Monte Villa Parkway, Suite 310 Bothell WASHINGTON 98021
Phone	4254021400
Name of Person for Whose Account the Securities are To Be Sold	KAREN FOSTER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	500	9930.00	48300000	03/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/09/2026	Exercise of Stock Options	Issuer			500	03/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for KAREN FOSTER 3303 Monte Villa Parkway, Suite 310 Bothell WA 98021	Common	03/05/2026	96923	1953163.22
10b5-1 Sales for KAREN FOSTER 3303 Monte Villa Parkway, Suite 310 Bothell WA 98021	Common	03/03/2026	418	8669.32
10b5-1 Sales for KAREN FOSTER 3303 Monte Villa Parkway, Suite 310 Bothell WA 98021	Common	01/06/2026	335	8572.65

144: Remarks and Signature

Remarks
Date of Notice	03/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/04/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Karen Foster
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)